Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold‐adapted vaccine recombinant in which vaccine‐associated illness occurred in normal volunteers
Identifieur interne : 002264 ( Main/Exploration ); précédent : 002263; suivant : 002265Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold‐adapted vaccine recombinant in which vaccine‐associated illness occurred in normal volunteers
Auteurs : Robert F. Betts [États-Unis] ; R. Gordon Douglas ; Hunien F. Maassab Jr. ; Dan C. Deborde ; Mary Lou Clements [États-Unis] ; Brian R. MurphySource :
- Journal of Medical Virology [ 0146-6615 ] ; 1988-10.
Descripteurs français
- KwdFr :
- MESH :
- effets indésirables : Vaccins antigrippaux, Vaccins atténués, Vaccins synthétiques.
- microbiologie : Partie nasale du pharynx.
- épidémiologie : Grippe humaine.
- étiologie : Grippe humaine.
- Adulte, Humains, Relation dose-effet des médicaments.
English descriptors
- KwdEn :
- MESH :
- chemical , adverse effects : Influenza Vaccines, Vaccines, Attenuated, Vaccines, Synthetic.
- epidemiology : Influenza, Human.
- etiology : Influenza, Human.
- microbiology : Nasopharynx.
- Teeft :
- Adult, Adult volunteers, Antibody response, Attenuated, Betts, Clements, Different doses, Donor virus, Dos, Dose response, Dose-Response Relationship, Drug, Experimental challenge, Genes coding, Hemagglutinin, High rate, Humans, Immunity murphy, Infection frequency, Infectious diseases, Infectivity, Infectivity titer, Influenza, Influenza vaccine reactionicity, Influenza virus, Internal genes, Lower doses, Maassab, Nasal washes, Natural influenza, Reactogenicity, Reassortant, Reassortant vaccines, Reassortant virus, Recombinant, Recombinant virus, Symptom, Systemic complaints, Systemic symptoms, Undiluted vaccine, Vaccine, Vaccine administration, Vaccine development, Vaccine reactogenicity, Vaccine virus, Virus, Virus inoculum, Virus vaccine, Virus vaccines, Wild type, Young children.
Abstract
Live attenuated cold‐adapted influenza vaccine is undergoing evaluation in man. Several strains have proven to be safe, immunogenic, nontransmissible, and protective against experimental challenge. In this study of A/Peking/2/79(H3N2), with six internal genes from the cold‐adapted (Ca) parent A/Ann Arbor/6/60(H2N2), we encountered at the highest input multiplicity, 28% illness rate among individuals infected with vaccine. Reversion to wild type and excessive viral replication did not occur. Physical characteristics of the vaccine were similar to nonreactogenic vaccine A/Washington/897/80(H3N2). At ten‐ and 100‐fold lower input multiplicities, infection frequency was maintained, but reactions did not occur. We compared the observations in this study with those made in a similar study of A/Scotland/840/74(H3N2), a cold‐adapted vaccine with five genes from the Ca parent in which reactogenicity also was noted. The dose of vaccine virus in relation to tissue culture infectious doses required to infect 50% of susceptibles (HID50) was proportionally lower for both A/Peking/2/79(H3N2) and A/Scotland/80(H3N2). Hence, when the vaccine was undiluted the recipients were inoculated with more than 100 HID50. We concluded that the very high input could be avoided if vaccines were screened beginning at 1/1,000 of maximum titers. Ca vaccines must be safe before they undergo field trials.
Url:
DOI: 10.1002/jmv.1890260209
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000104
- to stream Istex, to step Curation: 000104
- to stream Istex, to step Checkpoint: 000F77
- to stream PubMed, to step Corpus: 000470
- to stream PubMed, to step Curation: 000470
- to stream PubMed, to step Checkpoint: 000424
- to stream Ncbi, to step Merge: 001038
- to stream Ncbi, to step Curation: 001038
- to stream Ncbi, to step Checkpoint: 001038
- to stream Main, to step Merge: 002372
- to stream Main, to step Curation: 002264
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold‐adapted vaccine recombinant in which vaccine‐associated illness occurred in normal volunteers</title><author><name sortKey="Betts, Robert F" sort="Betts, Robert F" uniqKey="Betts R" first="Robert F." last="Betts">Robert F. Betts</name></author><author><name sortKey="Douglas, R Gordon" sort="Douglas, R Gordon" uniqKey="Douglas R" first="R. Gordon" last="Douglas">R. Gordon Douglas</name></author><author><name sortKey="Maassab Jr, Hunien F" sort="Maassab Jr, Hunien F" uniqKey="Maassab Jr H" first="Hunien F." last="Maassab Jr.">Hunien F. Maassab Jr.</name></author><author><name sortKey="Deborde, Dan C" sort="Deborde, Dan C" uniqKey="Deborde D" first="Dan C." last="Deborde">Dan C. Deborde</name></author><author><name sortKey="Clements, Mary Lou" sort="Clements, Mary Lou" uniqKey="Clements M" first="Mary Lou" last="Clements">Mary Lou Clements</name></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:DA95D4B0A16E872B4AE7E2BAC0D1D75D870D0613</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1002/jmv.1890260209</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-MSPH10MV-Q/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000104</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000104</idno><idno type="wicri:Area/Istex/Curation">000104</idno><idno type="wicri:Area/Istex/Checkpoint">000F77</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000F77</idno><idno type="wicri:doubleKey">0146-6615:1988:Betts R:analysis:of:virus</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:3183640</idno><idno type="wicri:Area/PubMed/Corpus">000470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000470</idno><idno type="wicri:Area/PubMed/Curation">000470</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000470</idno><idno type="wicri:Area/PubMed/Checkpoint">000424</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000424</idno><idno type="wicri:Area/Ncbi/Merge">001038</idno><idno type="wicri:Area/Ncbi/Curation">001038</idno><idno type="wicri:Area/Ncbi/Checkpoint">001038</idno><idno type="wicri:doubleKey">0146-6615:1988:Betts R:analysis:of:virus</idno><idno type="wicri:Area/Main/Merge">002372</idno><idno type="wicri:Area/Main/Curation">002264</idno><idno type="wicri:Area/Main/Exploration">002264</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold‐adapted vaccine recombinant in which vaccine‐associated illness occurred in normal volunteers</title><author><name sortKey="Betts, Robert F" sort="Betts, Robert F" uniqKey="Betts R" first="Robert F." last="Betts">Robert F. Betts</name><affiliation></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Correspondence address: Infectious Disease Unit, University of Rochester, Rochester</wicri:cityArea></affiliation></author><author><name sortKey="Douglas, R Gordon" sort="Douglas, R Gordon" uniqKey="Douglas R" first="R. Gordon" last="Douglas">R. Gordon Douglas</name><affiliation></affiliation><affiliation><wicri:noCountry code="subField">York</wicri:noCountry></affiliation></author><author><name sortKey="Maassab Jr, Hunien F" sort="Maassab Jr, Hunien F" uniqKey="Maassab Jr H" first="Hunien F." last="Maassab Jr.">Hunien F. Maassab Jr.</name><affiliation><wicri:noCountry code="no comma">University of Michigan</wicri:noCountry></affiliation></author><author><name sortKey="Deborde, Dan C" sort="Deborde, Dan C" uniqKey="Deborde D" first="Dan C." last="Deborde">Dan C. Deborde</name><affiliation><wicri:noCountry code="no comma">University of Michigan</wicri:noCountry></affiliation></author><author><name sortKey="Clements, Mary Lou" sort="Clements, Mary Lou" uniqKey="Clements M" first="Mary Lou" last="Clements">Mary Lou Clements</name><affiliation wicri:level="4"><country>États-Unis</country><placeName><settlement type="city">College Park (Maryland)</settlement><region type="state">Maryland</region></placeName><orgName type="university">Université du Maryland</orgName></affiliation></author><author><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name><affiliation><wicri:noCountry code="subField">Laboratory</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of Medical Virology</title><title level="j" type="alt">JOURNAL OF MEDICAL VIROLOGY</title><idno type="ISSN">0146-6615</idno><idno type="eISSN">1096-9071</idno><imprint><biblScope unit="vol">26</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="175">175</biblScope><biblScope unit="page" to="183">183</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>New York</pubPlace><date type="published" when="1988-10">1988-10</date></imprint><idno type="ISSN">0146-6615</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0146-6615</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Humans</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (epidemiology)</term><term>Influenza, Human (etiology)</term><term>Nasopharynx (microbiology)</term><term>Vaccines, Attenuated (adverse effects)</term><term>Vaccines, Synthetic (adverse effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Grippe humaine (épidémiologie)</term><term>Grippe humaine (étiologie)</term><term>Humains</term><term>Partie nasale du pharynx (microbiologie)</term><term>Relation dose-effet des médicaments</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins atténués (effets indésirables)</term><term>Vaccins synthétiques (effets indésirables)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term><term>Vaccines, Attenuated</term><term>Vaccines, Synthetic</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term><term>Vaccins atténués</term><term>Vaccins synthétiques</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Partie nasale du pharynx</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Nasopharynx</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adult</term><term>Adult volunteers</term><term>Antibody response</term><term>Attenuated</term><term>Betts</term><term>Clements</term><term>Different doses</term><term>Donor virus</term><term>Dos</term><term>Dose response</term><term>Dose-Response Relationship, Drug</term><term>Experimental challenge</term><term>Genes coding</term><term>Hemagglutinin</term><term>High rate</term><term>Humans</term><term>Immunity murphy</term><term>Infection frequency</term><term>Infectious diseases</term><term>Infectivity</term><term>Infectivity titer</term><term>Influenza</term><term>Influenza vaccine reactionicity</term><term>Influenza virus</term><term>Internal genes</term><term>Lower doses</term><term>Maassab</term><term>Nasal washes</term><term>Natural influenza</term><term>Reactogenicity</term><term>Reassortant</term><term>Reassortant vaccines</term><term>Reassortant virus</term><term>Recombinant</term><term>Recombinant virus</term><term>Symptom</term><term>Systemic complaints</term><term>Systemic symptoms</term><term>Undiluted vaccine</term><term>Vaccine</term><term>Vaccine administration</term><term>Vaccine development</term><term>Vaccine reactogenicity</term><term>Vaccine virus</term><term>Virus</term><term>Virus inoculum</term><term>Virus vaccine</term><term>Virus vaccines</term><term>Wild type</term><term>Young children</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Humains</term><term>Relation dose-effet des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Live attenuated cold‐adapted influenza vaccine is undergoing evaluation in man. Several strains have proven to be safe, immunogenic, nontransmissible, and protective against experimental challenge. In this study of A/Peking/2/79(H3N2), with six internal genes from the cold‐adapted (Ca) parent A/Ann Arbor/6/60(H2N2), we encountered at the highest input multiplicity, 28% illness rate among individuals infected with vaccine. Reversion to wild type and excessive viral replication did not occur. Physical characteristics of the vaccine were similar to nonreactogenic vaccine A/Washington/897/80(H3N2). At ten‐ and 100‐fold lower input multiplicities, infection frequency was maintained, but reactions did not occur. We compared the observations in this study with those made in a similar study of A/Scotland/840/74(H3N2), a cold‐adapted vaccine with five genes from the Ca parent in which reactogenicity also was noted. The dose of vaccine virus in relation to tissue culture infectious doses required to infect 50% of susceptibles (HID50) was proportionally lower for both A/Peking/2/79(H3N2) and A/Scotland/80(H3N2). Hence, when the vaccine was undiluted the recipients were inoculated with more than 100 HID50. We concluded that the very high input could be avoided if vaccines were screened beginning at 1/1,000 of maximum titers. Ca vaccines must be safe before they undergo field trials.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li><li>État de New York</li></region><settlement><li>College Park (Maryland)</li></settlement><orgName><li>Université du Maryland</li></orgName></list><tree><noCountry><name sortKey="Deborde, Dan C" sort="Deborde, Dan C" uniqKey="Deborde D" first="Dan C." last="Deborde">Dan C. Deborde</name><name sortKey="Douglas, R Gordon" sort="Douglas, R Gordon" uniqKey="Douglas R" first="R. Gordon" last="Douglas">R. Gordon Douglas</name><name sortKey="Maassab Jr, Hunien F" sort="Maassab Jr, Hunien F" uniqKey="Maassab Jr H" first="Hunien F." last="Maassab Jr.">Hunien F. Maassab Jr.</name><name sortKey="Murphy, Brian R" sort="Murphy, Brian R" uniqKey="Murphy B" first="Brian R." last="Murphy">Brian R. Murphy</name></noCountry><country name="États-Unis"><region name="État de New York"><name sortKey="Betts, Robert F" sort="Betts, Robert F" uniqKey="Betts R" first="Robert F." last="Betts">Robert F. Betts</name></region><name sortKey="Clements, Mary Lou" sort="Clements, Mary Lou" uniqKey="Clements M" first="Mary Lou" last="Clements">Mary Lou Clements</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002264 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002264 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:DA95D4B0A16E872B4AE7E2BAC0D1D75D870D0613
|texte= Analysis of virus and host factors in a study of A/Peking/2/79 (H3N2) cold‐adapted vaccine recombinant in which vaccine‐associated illness occurred in normal volunteers
}}
| This area was generated with Dilib version V0.6.33. |  |